Compare Crispr Therapeutics AG (CRSP) vs Huntington Ingalls Industries Inc (HII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Huntington Ingalls Industries Inc — how do they compare? Crispr Therapeutics AG trades at $50.75 (market cap $4.97B), while Huntington Ingalls Industries Inc trades at $282.25 (market cap $11.03B). The key difference: Huntington Ingalls Industries Inc is far larger — about 2.2× Crispr Therapeutics AG's market cap, and Huntington Ingalls Industries Inc pays a 1.97% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | HII | |
|---|---|---|
Market Cap | $4.97B | $11.03B |
Sector | Health | Technology |
52-Week High | $76.78 | $453.73 |
52-Week Low | $44.34 | $252.93 |
Enterprise Value | $3.32B | $13.75B |
Dividend Yield | — | 1.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
HII trades at $284.86, down 0.43% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company shows stable fundamentals with a P/E of 18.19 and net income margin of 4.71%, supported by recent earnings beats. Recent news highlights contract awards and leadership additions, reinforcing its defense sector presence.
The outlook is cautiously optimistic with a consensus price target of $354.50, implying significant upside. Risks include execution on new contracts and defense budget dependencies, but analyst sentiment leans positive with 44% buy ratings. The upcoming Q2 2026 earnings report on July 30 will be a key catalyst for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Huntington Ingalls Industries Inc
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →
